| 常用名 | 醋酸特立帕肽 | CAS号 | 52232-67-4 |
|---|---|---|---|
| 价格 | $106.78/10mg $1877.39/1g | 纯度 | 99.69% |
| 备货期 | 3天 | 库存 | 询单 |
| 产品网页 | http://www.zhaokebio.com | ||
| 产品详情(用途,包装等)
Teriparatide is a recombinant human parathyroid hormone (PTH) analog consisting of the biologically active N-terminal portion of PTH (amino acids 1-34). It is the first and only anabolic osteoporosis therapy approved for the treatment of severe osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis. By stimulating osteoblast activity, Teriparatide increases bone mineral density (BMD) and improves bone microarchitecture, reducing the risk of vertebral and non-vertebral fractures. Product Highlights: First Anabolic Osteoporosis Therapy-Only anabolic (bone-building) agent among osteoporosis treatments; stimulates new bone formation by activating osteoblasts rather than merely inhibiting resorption. Addresses a critical unmet need for patients with severe osteoporosis who have failed anti-resorptive therapy. Clinically Proven Fracture Reduction-Pivotal trials demonstrate 65% reduction in vertebral fractures and 53% reduction in non-vertebral fractures vs placebo at 18-19 months. Strong clinical evidence supports premium pricing and broad formulary coverage in global markets. Large-Scale GMP Supply-Multi-kilogram GMP production capacity with validated recombinant peptide synthesis processes and comprehensive stability programs. Reliable commercial supply for formulation partners developing prefilled syringes, pen injectors, and multidose presentations. Biosimilar & Generic Development-Well-characterized reference standard available for biosimilar development programs pursuing interchangeability designation. Supports emerging market generic manufacturers and biosimilar developers with regulatory-compliant API and documentation. |